Stock Ticker

  • Loading stock data...

Merck & Co., Inc. (NYSE:MRK) Achieves Limited Success Of Steglatro In Reducing The Risk Of Patients With Total Hospitalizations

Merck & Co., Inc.  (NYSE:MRK) reported only limited success in lowering patients’ total hospitalizations with heart failures. According to recent clinical data, Merck’s Steglatro could overall reduce cardiovascular death or total hospitalization risks by just 17% or lower the risk of the patient by 30%. In a statement, Merck said the first hospitalizations rate remains […]

Merck & Co., Inc. (NYSE:MRK) Gets FDA Nod For ZERBAXA

Merck & Co., Inc. (NYSE:MRK) reported that the U.S. Food and Drug Administration has approved expanded use of its antibiotic to cure hospital-acquired pneumonia in people 18 years and older. This nod comes on the back of the treatment’s late-stage study data, which indicated that Zerbaxa was effective as an antibacterial drug. Zerbaxa was included […]

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Closes A Licensing Deal With Merck & Co., Inc (NYSE:MRK)

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has today moved forward to make an announcement regarding its signing up into some definitive agreement where it was expected to grant Merck & Co., Inc (NYSE:MRK), which is commonly referred to as MSD Animal Health beyond borders of the United States and Canada as well with the full rights to […]

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Signs a Licensing Deal with Merck & Co., Inc. (NYSE:MRK) Animal Health

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) completes a Definitive Agreement giving Merck & Co., Inc. (NYSE:MRK) Animal Health the rights to build up and distribute Aurinia’s patented nano-micellar cyclosporin ophthalmic solution (VOS) for treating dry eye disorders in dogs. In this agreement, the Aurinia will obtain an upfront payment and they could receive more recompense which will […]

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Gains $550,000 As EMA Approves Merck & Co., Inc. (NYSE:MRK)’S NOXAFIL®

Boston, MA 09/29/2014 (wallstreetpr) – Ligand Pharmaceuticals Inc. (NASDAQ:LGND) declared that it will receive as much as $550,000 as milestone payment from Merck & Co., Inc. (NYSE:MRK), after the later gained approval for one of its drugs from the European Medicines Agency (EMA). Merck, which is called MSD in countries other than the U.S. and […]

Market Recap: MGM Resorts (MGM), Northstar Realty Finance (NRF) Merck & Co. (MRK)

Boston, MA 09/24/2014 (wallstreetpr) – MGM Resorts International (NYSE:MGM) managed to edge up above 1% on Tuesday even as analysts at Wells Fargo (WFC) eventually moved to downgrade Macau stocks. The firm downgraded Macau because of the almost ever-increasing negative news concerning casino business in the Chinese gambling capital. MGM Resorts and its peers in […]

Merck & Co., Inc. (NYSE:MRK) Loses Pressure On Pharmaceutical Unit By Acquiring Sigma-Aldrich Corporation (NASDAQ:SIAL)

Boston, MA 09/23/2014 (wallstreetpr) – Merck & Co., Inc. (NYSE:MRK), the Germany-based pharmaceutical company, has offered to buy Sigma-Aldrich Corporation (NASDAQ:SIAL) for $17 billion. Terms Of Deal Sigma-Aldrich Corporation (NASDAQ:SIAL) is among the biggest manufacturers of chemicals and biological substances used in labs. The life science and high-technology Company had recorded sales of as much […]

Merck & Co., Inc. (NYSE:MRK) and Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Enter Into A Licensing Agreement Worth $ 80 million for Tildrakizumab

Boston, MA 09/18/2014 (wallstreetpr) – According to reports, pharmaceutical giant Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) has decided to enter into a licensing agreement with Merck & Co., Inc. (NYSE:MRK). The deal has been signed keeping Tildrakizumab in context. It is one of the well-acclaimed investigational therapeutic antibody candidates in the world that is to be […]

Merck & Co. Inc. (NYSE:MRK) Open To Buying Big Acquisitions

Boston, MA 06/13/2014 (wallstreetpr) – Merck & Co. Inc. (NYSE:MRK) research Chief Roger Perlmutter has stated that the company is more than open to the idea of buying big acquisitions of biotech companies rather than go forward and obtain drug development technologies. Mr. Perlmutter reiterated the company’s attitude for new deals at the back of […]

Merck & Co., Inc. (NYSE:MRK) To Buy Idenix To Extend Its Presence In Hepatitis C

Boston, MA 06/10/2014 (wallstreetpr) – Global health care company Merck & Co., Inc. (NYSE:MRK) announced that it struck a definite agreement to buy Idenix Pharmaceuticals Inc (NASDAQ:IDIX), a bio-pharmaceutical company, for $3.85 billion. The acquisition is expected to help Merck widen its portfolio on Hepatitis C. Acquisition of Idenix As part of the definitive deal, […]

Merck & Co., Inc. (NYSE:MRK) Designed Effective Drug For Skin And Lung Cancer

Boston, MA 06/04/2014 (wallstreetpr) – Merck & Co., Inc. (NYSE:MRK) is a globally recognized heath care company, which provides innovative heath products across the globe. The company is familiar in the name of MSD outside the U.S. and Canada. On Monday, June 2, 2014 the company declared that the highly anticipated immunotherapy proved its usefulness […]

Stocks On The Spotlight: Sunedison Inc (NYSE:SUNE), Ocwen Financial Corp (NYSE:OCN), Merck & Co., Inc. (NYSE:MRK)

Boston, MA 02/24/2014 (wallstreetpr) – Sunedison Inc (NYSE:SUNE) was among the winners of clean energy permits in India. The company was alongside Azure Power India awarded 100 megawatts capacity each in the first national solar permits auction since 2012. The strategy that helped SUNE and other winners was that they placed the lowest bids. The […]

Milestone Stocks: VimpelCom Ltd (ADR) (NASDAQ:VIP), Delta Air Lines, Inc. (NYSE:DAL), Merck & Co., Inc. (NYSE:MRK)

Boston, MA 01/29/2014 (wallstreetpr) – VimpelCom Ltd (ADR) (NASDAQ:VIP) sank its lowest since 2012 in Tuesday trading after the multinational company withheld final dividend for 2013 and declared that future dividend payouts will be lower. What the company is trying to do is fixing its problems, and more so, preparing for the hard times when […]

Merck & Co., Inc. (NYSE:MRK) Falters Over Januvia Sales And Poor Q3 Results

Boston, MA 10/30/2013 (wallstreetpr) – Merck & Co., Inc. (NYSE:MRK) shares take a tumble following the poor weak earnings the company posted for the third quarter of 2013. The company continues to be troubled by patent issues with key drugs, which was further complicated by currency flip-flops. Both of the above primary drivers for the company […]

Merck & Co., Inc. (NYSE:MRK) To Save $2.5 Billion In Restructuring, Good News To Investors

Boston, MA 10/22/2013 (wallstreetpr) – After a seemingly good rally through last week, Merck & Co., Inc. (NYSE:MRK) eventually succumbed to the volatility in the health care sector to close the week on Friday, October 18, down by 1.06% to settle at $46.61. The global health care company is now undergoing restructuring efforts to see if it […]

Sign Up To Get Our Latest Stocks Alerts